Barcelona And New York

BARCELONA and NEW YORK, January 4, 2011 - - ATTAIN results confirm clinically significant bronchodilation and improvement ofsymptoms in COPD patients treated with aclidinium bromide twice daily - Regulatory filings in Europe and USA for aclidinium bromide monotherapy are planned for mid 2011 - Positive results of two Phase IIb studies with the fixed dose combination of aclidinium bromide and formoterol will enable Phase III to start in second half 2011 Almirall, S.A.